Abstract: The present invention provides a front panel of an air cooler, which comprises a front panel body and an opening arranged on the front panel body; an air outlet panel is arranged in the opening through an axis pin mechanism; wherein, the air outlet panel swings with the axis pin mechanism as the axis; at least one locking mechanism for limiting the swing of the air outlet panel is arranged in the opening.

Abstract: The present application relates to a chimeric antigen receptor, comprising a first antigen binding domain and a second antigen binding domain. The first antigen binding domain targets a G protein-coupled receptor class C group 5 member D (GPRC5D) protein, and the second antigen binding domain targets the GPRC5D protein. The present application further provides a cell comprising the chimeric antigen receptor and use thereof.

Abstract: Disclosed is a method for promoting immune cell proliferation. The method comprises the following step: upregulating the expression of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells.

Abstract: A chimeric antigen receptor (CAR), containing a BCMA (B cell maturation antigen) binding domain. The BCMA binding domain includes an antibody or an antigen-binding fragment of an antibody that specifically binds to BCMA. The antibody contains a heavy-chain complementarity determining region 3 (HCDR3), a heavy-chain complementarity determining region 2 (HCDR2), and a heavy-chain complementarity determining region 1 (HCDR1). The HCDR3 contains an amino acid sequence as set forth in SEQ ID NO: 25, the HCDR2 contains an amino acid sequence as set forth in SEQ ID NO: 41, and the HCDR1 contains an amino acid sequence as set forth in SEQ ID NO: 21.

Abstract: An isolated antigen binding protein capable of binding to a G protein-coupled receptor, class C, group 5, member D (GPRCSD) protein with an EC50 value of 1.0 ?g/mL is described. A chimeric antigen receptor comprising the isolated antigen binding protein and its use in the treatment of tumors is also described.

Abstract: The present application relates to a chimeric antigen receptor (CAR), comprising a GPC3 binding domain, a transmembrane domain, a costimulatory domain and an intracellular signaling domain, the GPC3 binding domain comprises an antibody or a fragment thereof which specifically binding to GPC3, the antibody comprises a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2) and a light chain complementary determining region 3 (LCDR3), the amino acid sequence of the LCDR1 is as set forth in SEQ ID NO: 16, the amino acid sequence of the LCDR2 is as set forth in SEQ ID NO: 17 and the amino acid sequence of the LCDR3 is as set forth in SEQ ID NO: 18. The present application also relates to an isolated nucleic acid encoding the CAR, a vector comprising the nucleic acid, an immune effector cell comprising the nucleic acid or the vector and a preparation method thereof as well as a use of the CAR.

Abstract: Provided is a modified immune cell, comprising a chimeric antigen receptor and/or a coding element therefor, or comprising a T cell receptor and/or a coding element therefor. The immune cell further comprises: leptin and/or a functional fragment thereof; and/or, a leptin receptor and/or a functional fragment thereof, and the expression quantity of the leptin receptor and/or the functional fragment thereof in the immune cell is increased compared with that in an immune cell without the corresponding modification. In addition, also provided is another modified immune cell, comprising leptin and/or a functional fragment thereof, and/or, a leptin receptor and/or a functional fragment thereof, and a low-density lipoprotein-receptor-related protein or a fragment thereof.